Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.67, beating the estimate of USD -0.745.EBIT: As of FY2026 Q1, the actual value is USD -24.95 M.<h3>Operational Metrics</h3><ul><li>Research &amp; Development Expenses: Research and development expenses for LB Pharmaceuticals Inc were $14.6 million for the three months ended March 31, 2026, an increase of $11.2 million compared to $3.4 million for the three months ended March 31, 2025. </li><li>General &amp; Administrative Expenses: General and administrative expenses were $7.5 million for the three months ended March 31, 2026, an increase of $4.5 million from $3.0 million for the three months ended March 31, 2025. </li><li>Net Loss: LB Pharmaceuticals Inc reported a net loss of - $19.1 million for the three months ended March 31, 2026, compared to a net loss of - $5.3 million for the same period in 2025. </li><li>Total Operating Loss: The total operating loss was - $22,104 thousand for Q1 2026, compared to - $6,429 thousand for Q1 2025. </li><li>Loss Before Income Tax: Loss before income tax was - $19,054 thousand for Q1 2026, compared to - $5,306 thousand for Q1 2025. </li><li>Income Tax Provision: The income tax provision was $0 for both Q1 2026 and Q1 2025. </li></ul><h3>Other Financial Metrics</h3><ul><li>Interest Income: Interest income was $2,850 thousand for Q1 2026, up from $236 thousand for Q1 2025. </li><li>Realized Gain on Sale of Marketable Securities, Net: This metric was $0 for Q1 2026, compared to $119 thousand for Q1 2025. </li><li>Gain on Change in Fair Value of Derivative Instruments: This gain was $200 thousand for Q1 2026, compared to $768 thousand for Q1 2025. </li><li>Total Non-Operating Income: Total non-operating income amounted to $3,050 thousand for Q1 2026, compared to $1,123 thousand for Q1 2025. </li></ul><h3>Cash Position</h3><ul><li>Cash, Cash Equivalents, and Marketable Securities: As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $365.6 million, an increase from $295.2 million as of December 31, 2025. </li></ul><h3>Balance Sheet Highlights (in thousands)</h3><ul><li>Total Assets: Total assets were $393,482 as of March 31, 2026, compared to $312,934 as of December 31, 2025. </li><li>Total Liabilities: Total liabilities were $14,789 as of March 31, 2026, compared to $11,624 as of December 31, 2025. </li><li>Total Stockholders’ Equity: Total stockholders’ equity stood at $378,693 as of March 31, 2026, compared to $301,310 as of December 31, 2025. </li></ul><h3>Outlook / Guidance</h3>LB Pharmaceuticals Inc expects its cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026, to fund operations into the second quarter of 2029. The company anticipates releasing topline data from the NOVA-2 trial in schizophrenia in the second half of 2027, and from the ILLUMINATE-1 trial in bipolar depression in the first quarter of 2028. Additionally, topline data from the adjunctive MDD trial is expected in the first half of 2029.

LB Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0